EMA/152079/2021

European Medicines Agency decision

P/0148/2021

of 16 April 2021

on the acceptance of a modification of an agreed paediatric investigation plan for valoctocogene roxaparvovec, (EMEA-002427-PIP01-18-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0148/2021

of 16 April 2021

on the acceptance of a modification of an agreed paediatric investigation plan for valoctocogene roxaparvovec, (EMEA-002427-PIP01-18-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0218/2019 issued on 17 June 2019,

Having regard to the application submitted by BioMarin International Limited on 27 November 2020 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 February 2021, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for valoctocogene roxaparvovec, solution for infusion, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to BioMarin International Limited, Shanbally, Ringaskiddy, County Cork, P43 R298 – Shanbally, Ireland.

EMA/PDCO/654615/2020
Amsterdam, 26 February 2021

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-002427-PIP01-18-M01

Scope of the application

Active substance(s):

Valoctocogene roxaparvovec

Condition(s):

Treatment of haemophilia A

Pharmaceutical form(s):

Solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

BioMarin International Limited

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, BioMarin International Limited submitted to the European Medicines Agency on 27 November 2020 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0218/2019 issued on 17 June 2019.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 4 January 2021.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition

Treatment of haemophilia A

2.1.1. Indication(s) targeted by the PIP

Treatment of patients with haemophilia A

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	3	**Study 1** Exploratory toxicity and efficacy study comparing FVIII expression levels between neonatal mice and sexually mature mice. **Study 2** Definitive juvenile toxicity study to assess the effect of BMN 270 in mice and to evaluate toxicity during post-natal development at varying ages. **Study 3** Dose range-finding juvenile toxicity study to assess the effects of BMN 270 in mice at the specific ages identified in study 2 and to support dose-selection.
Clinical studies	3	**Study 4** Open-label, single-arm, single dose trial to evaluate safety and efficacy of BMN 270 in children from 12 years to less than 18 years of age with haemophilia A.

		Study 5 Open-label, single-arm, single dose trial to evaluate safety and efficacy of BMN 270 in children from 6 years to less than 12 years of age with haemophilia A. **Study 6** Open-label, single-arm, single dose trial to evaluate safety and efficacy of BMN 270 in children from birth to less than 6 years of age with haemophilia A.
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2035
Deferral for one or more measures contained in the paediatric investigation plan:	Yes